PT3310809T - Formulação de anticorpo anti-cgrp - Google Patents

Formulação de anticorpo anti-cgrp

Info

Publication number: PT3310809T
Authority: PT; Portugal
Prior art keywords: antibody formulation; cgrp antibody; cgrp; formulation; antibody
Prior art date: 2015-06-17

Application number

PT167294834T

Other languages

English (en)

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-17

Filing date

2016-06-08

Publication date

2024-12-16

2016-06-08 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2024-12-16 Publication of PT3310809T publication Critical patent/PT3310809T/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT167294834T 2015-06-17 2016-06-08 Formulação de anticorpo anti-cgrp PT3310809T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201562180905P	2015-06-17	2015-06-17

Publications (1)

Publication Number	Publication Date
PT3310809T true PT3310809T (pt)	2024-12-16

Family

ID=56131672

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT167294834T PT3310809T (pt)	2015-06-17	2016-06-08	Formulação de anticorpo anti-cgrp

Country Status (30)

Country	Link
US (3)	US11498959B2 (pt)
EP (2)	EP4470557A3 (pt)
JP (1)	JP6438599B2 (pt)
KR (1)	KR102000867B1 (pt)
CN (3)	CN114948847A (pt)
AR (1)	AR104847A1 (pt)
AU (1)	AU2016280555B2 (pt)
BR (1)	BR112017023374A2 (pt)
CA (1)	CA2984185A1 (pt)
DK (1)	DK3310809T3 (pt)
EA (1)	EA037580B1 (pt)
ES (1)	ES3000607T3 (pt)
FI (1)	FI3310809T3 (pt)
HK (1)	HK1245813A1 (pt)
HR (1)	HRP20241660T1 (pt)
HU (1)	HUE069368T2 (pt)
IL (2)	IL292562A (pt)
JO (1)	JO3772B1 (pt)
LT (1)	LT3310809T (pt)
MA (1)	MA49726B1 (pt)
MX (1)	MX2017016199A (pt)
MY (1)	MY184266A (pt)
NZ (1)	NZ737046A (pt)
PL (1)	PL3310809T3 (pt)
PT (1)	PT3310809T (pt)
RS (1)	RS66243B1 (pt)
TW (1)	TWI725973B (pt)
UA (1)	UA120881C2 (pt)
WO (1)	WO2016205037A1 (pt)
ZA (1)	ZA201707324B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11951139B2 (en)	2015-11-30	2024-04-09	Seed Health, Inc.	Method and system for reducing the likelihood of osteoporosis
US11844720B2 (en)	2011-02-04	2023-12-19	Seed Health, Inc.	Method and system to reduce the likelihood of dental caries and halitosis
US11998479B2 (en)	2011-02-04	2024-06-04	Seed Health, Inc.	Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951140B2 (en)	2011-02-04	2024-04-09	Seed Health, Inc.	Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US20170114122A1 (en)	2015-10-23	2017-04-27	Alderbio Holdings Llc	Regulation of glucose metabolism using anti-cgrp antibodies
US11826388B2 (en)	2013-12-20	2023-11-28	Seed Health, Inc.	Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11998574B2 (en)	2013-12-20	2024-06-04	Seed Health, Inc.	Method and system for modulating an individual's skin microbiome
US11969445B2 (en)	2013-12-20	2024-04-30	Seed Health, Inc.	Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11980643B2 (en)	2013-12-20	2024-05-14	Seed Health, Inc.	Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12246043B2 (en)	2013-12-20	2025-03-11	Seed Health, Inc.	Topical application to treat acne vulgaris
US12005085B2 (en)	2013-12-20	2024-06-11	Seed Health, Inc.	Probiotic method and composition for maintaining a healthy vaginal microbiome
US11833177B2 (en)	2013-12-20	2023-12-05	Seed Health, Inc.	Probiotic to enhance an individual's skin microbiome
US11839632B2 (en)	2013-12-20	2023-12-12	Seed Health, Inc.	Topical application of CRISPR-modified bacteria to treat acne vulgaris
US9896502B2 (en)	2014-03-21	2018-02-20	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10556945B2 (en)	2014-03-21	2020-02-11	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP3515488A1 (en) *	2016-09-23	2019-07-31	Teva Pharmaceuticals International GmbH	Treating cluster headache
JP6937368B2 (ja)	2016-09-23	2021-09-22	テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー	難治性片頭痛の治療方法
MX2019010397A (es)	2017-03-02	2020-08-20	Beth Israel Deaconess Medical Ct Inc	Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
TWI754772B (zh) *	2017-09-06	2022-02-11	美商美國禮來大藥廠	用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
JP2021519790A (ja) *	2018-04-02	2021-08-12	アムジェンインコーポレイテッド	エレヌマブ組成物及びその使用
WO2019231800A1 (en) *	2018-05-31	2019-12-05	Eli Lilly And Company	Anti-cgrp antibodies for treating menstrual-related migraines
PH12021551478A1 (en)	2019-01-08	2022-05-02	H Lundbeck As	Acute treatment and rapid treatment of headache using anti-cgrp antibodies
KR20220004053A (ko) *	2019-05-02	2022-01-11	하. 룬드벡 아크티에셀스카브	항-cgrp 항체를 사용하는 두통의 치료
US20240139171A1 (en)	2021-03-02	2024-05-02	Cgrp Diagnostics Gmbh	Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en)	2021-08-24	2023-03-02	Cgrp Diagnostics Gmbh	Preventative treatment of migraine

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK282483B6 (sk)	1992-10-02	2002-02-05	Genetics Institute, Inc.	Stabilná kompozícia koagulačného faktora VIII, spôsob jej prípravy a stabilizácie
TWI240627B (en)	1996-04-26	2005-10-01	Chugai Pharmaceutical Co Ltd	Erythropoietin solution preparation
NZ532896A (en) *	2001-11-08	2007-08-31	Pdl Biopharma Inc	Stable liquid pharmaceutical formulation of IGG antibodies including daclizumab and fontolizumab
SI3417875T1 (sl)	2003-02-10	2021-01-29	Biogen Ma Inc.	Formulacija imunoglobulina in metode za njegovo pripravo
EP1841456A2 (en)	2005-01-28	2007-10-10	Wyeth	Stabilized liquid polypeptide formulations
GT200600031A (es)	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
AR054233A1 (es)	2005-03-08	2007-06-13	Pharmacia & Upjohn Co Llc	Composiciones de anticuerpos igg2
US9168286B2 (en) *	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
NZ597082A (en) *	2005-10-13	2013-11-29	Human Genome Sciences Inc	Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
EA015526B1 (ru) *	2005-11-14	2011-08-30	Ринат Ньюросайенс Корп.	Антагонистические антитела против пептида, связанного с геном кальцитонина, и способы их применения
WO2007123765A2 (en)	2006-03-31	2007-11-01	Human Genome Sciences Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
MX2009006199A (es)	2006-12-11	2009-06-22	Hoffmann La Roche	Formulacion parenteral de anticuerpos abeta.
AR064826A1 (es)	2007-01-09	2009-04-29	Wyeth Corp	Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa
CA2681743A1 (en) *	2007-03-22	2008-09-25	Imclone Llc	Stable antibody formulations
US20110130544A1 (en)	2007-03-30	2011-06-02	Medimmune, Llc	Antibodies with decreased deamidation profiles
US20080292625A1 (en) *	2007-04-18	2008-11-27	Sally Schroeter	Prevention and treatment of cerebral amyloid angiopathy
JP5642683B2 (ja) *	2008-09-19	2014-12-17	ファイザー・インク	安定な液体抗体配合物
CA2738243C (en)	2008-10-29	2020-09-29	Wyeth Llc	Formulations of single domain antigen binding molecules
CN102438652B (zh) *	2008-11-12	2014-08-13	米迪缪尼有限公司	抗体制剂
RU2011126338A (ru) *	2008-11-28	2013-01-10	Эбботт Лэборетриз	Стабильные композиции антител и способы их стабилизации
EP2196476A1 (en)	2008-12-10	2010-06-16	Novartis Ag	Antibody formulation
EP2403532A4 (en) *	2009-03-06	2012-12-05	Medimmune Llc	HUMANIZED ANTI-CD19 ANTIBODY FORMULATIONS
JO3417B1 (ar) *	2010-01-08	2019-10-20	Regeneron Pharma	الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3330B1 (ar) *	2010-06-10	2019-03-13	Lilly Co Eli	الأجسام المضادة cgrp
PT3246044T (pt) *	2010-08-23	2021-02-15	Wyeth Llc	Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
CN103429264A (zh) *	2011-03-31	2013-12-04	默沙东公司	针对人程序性死亡受体pd-1的抗体的稳定制剂和有关的治疗
HUE055505T2 (hu) *	2011-05-20	2021-11-29	H Lundbeck As	Anti-CGRP készítmények és alkalmazásuk
TW201326207A (zh)	2011-10-24	2013-07-01	Abbvie Inc	抗ｔｎｆ免疫結合物
WO2014031718A1 (en) *	2012-08-23	2014-02-27	Merck Sharp & Dohme Corp.	Stable formulations of antibodies to tslp
JP2016505633A (ja) *	2013-01-24	2016-02-25	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	ＴＮＦα抗原結合性タンパク質
US9896502B2 (en) *	2014-03-21	2018-02-20	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

2016
- 2016-06-01 AR ARP160101603A patent/AR104847A1/es not_active Application Discontinuation
- 2016-06-02 TW TW105117447A patent/TWI725973B/zh active
- 2016-06-05 JO JOP/2016/0111A patent/JO3772B1/ar active
- 2016-06-08 US US15/578,263 patent/US11498959B2/en active Active
- 2016-06-08 AU AU2016280555A patent/AU2016280555B2/en active Active
- 2016-06-08 EP EP24201727.5A patent/EP4470557A3/en active Pending
- 2016-06-08 JP JP2017564734A patent/JP6438599B2/ja active Active
- 2016-06-08 MA MA49726A patent/MA49726B1/fr unknown
- 2016-06-08 UA UAA201712093A patent/UA120881C2/uk unknown
- 2016-06-08 CA CA2984185A patent/CA2984185A1/en active Pending
- 2016-06-08 RS RS20241326A patent/RS66243B1/sr unknown
- 2016-06-08 CN CN202210229605.2A patent/CN114948847A/zh active Pending
- 2016-06-08 MX MX2017016199A patent/MX2017016199A/es unknown
- 2016-06-08 KR KR1020177035870A patent/KR102000867B1/ko active Protection Beyond IP Right Term
- 2016-06-08 NZ NZ73704616A patent/NZ737046A/en unknown
- 2016-06-08 PT PT167294834T patent/PT3310809T/pt unknown
- 2016-06-08 EA EA201792359A patent/EA037580B1/ru not_active IP Right Cessation
- 2016-06-08 BR BR112017023374-6A patent/BR112017023374A2/pt active Search and Examination
- 2016-06-08 CN CN202410340972.9A patent/CN118356393A/zh active Pending
- 2016-06-08 HR HRP20241660TT patent/HRP20241660T1/hr unknown
- 2016-06-08 EP EP16729483.4A patent/EP3310809B1/en active Active
- 2016-06-08 WO PCT/US2016/036407 patent/WO2016205037A1/en active Application Filing
- 2016-06-08 HU HUE16729483A patent/HUE069368T2/hu unknown
- 2016-06-08 ES ES16729483T patent/ES3000607T3/es active Active
- 2016-06-08 MY MYPI2017704814A patent/MY184266A/en unknown
- 2016-06-08 PL PL16729483.4T patent/PL3310809T3/pl unknown
- 2016-06-08 CN CN201680034297.0A patent/CN107787229A/zh active Pending
- 2016-06-08 LT LTEPPCT/US2016/036407T patent/LT3310809T/lt unknown
- 2016-06-08 DK DK16729483.4T patent/DK3310809T3/da active
- 2016-06-08 FI FIEP16729483.4T patent/FI3310809T3/fi active
- 2016-06-08 IL IL292562A patent/IL292562A/en unknown
2017
- 2017-10-27 ZA ZA2017/07324A patent/ZA201707324B/en unknown
- 2017-11-05 IL IL255443A patent/IL255443B/en unknown
2018
- 2018-04-26 HK HK18105442.3A patent/HK1245813A1/zh unknown
2021
- 2021-12-17 US US17/554,713 patent/US20220112277A1/en active Pending
2022
- 2022-08-08 US US17/883,072 patent/US20230159628A1/en active Pending

Also Published As

Publication number	Publication date
HRP20241660T1 (hr)	2025-02-14
AR104847A1 (es)	2017-08-16
HK1245813A1 (zh)	2018-08-31
LT3310809T (lt)	2025-01-10
US20180134772A1 (en)	2018-05-17
FI3310809T3 (fi)	2024-12-07
US20230159628A1 (en)	2023-05-25
MX2017016199A (es)	2018-03-01
IL255443B (en)	2022-06-01
DK3310809T3 (da)	2024-12-02
JP6438599B2 (ja)	2018-12-19
US11498959B2 (en)	2022-11-15
CA2984185A1 (en)	2016-12-22
TW201711697A (zh)	2017-04-01
IL255443A0 (en)	2017-12-31
CN118356393A (zh)	2024-07-19
KR20180002858A (ko)	2018-01-08
JO3772B1 (ar)	2021-01-31
EP3310809B1 (en)	2024-10-16
MA49726B1 (fr)	2025-02-28
EP4470557A3 (en)	2025-02-26
BR112017023374A2 (pt)	2018-07-24
NZ737046A (en)	2019-09-27
EA201792359A1 (ru)	2018-05-31
ZA201707324B (en)	2020-01-29
JP2018517727A (ja)	2018-07-05
US20220112277A1 (en)	2022-04-14
CN107787229A (zh)	2018-03-09
EP3310809A1 (en)	2018-04-25
EP4470557A2 (en)	2024-12-04
WO2016205037A1 (en)	2016-12-22
RS66243B1 (sr)	2024-12-31
TWI725973B (zh)	2021-05-01
MA49726A (fr)	2020-06-10
PL3310809T3 (pl)	2025-01-27
AU2016280555A1 (en)	2017-11-16
MY184266A (en)	2021-03-30
UA120881C2 (uk)	2020-02-25
KR102000867B1 (ko)	2019-07-16
IL292562A (en)	2022-06-01
CN114948847A (zh)	2022-08-30
HUE069368T2 (hu)	2025-02-28
EA037580B1 (ru)	2021-04-16
AU2016280555B2 (en)	2018-11-15
ES3000607T3 (en)	2025-03-03

Publication	Publication Date	Title
HK1245813A1 (zh)	2018-08-31	抗-cgrp抗體製劑
HK1254310A1 (zh)	2019-07-19	抗garp抗體
SG10201913864RA (en)	2020-03-30	Anti-LAG-3 Antibodies
IL248802A0 (en)	2017-01-31	Antibody formulation
IL256099A (en)	2018-02-28	antibody
SI3250593T1 (sl)	2022-09-30	Anti-transtiretin protitelesa
IL268889A (en)	2019-10-31	Anti-EPHA4 antibody
GB201508180D0 (en)	2015-06-24	Antibodies
GB201515351D0 (en)	2015-10-14	Antibody
GB201600871D0 (en)	2016-03-02	Antibody
LT3336185T (lt)	2022-02-10	Antikūnas
IL257368A (en)	2018-04-30	antibody
GB201503438D0 (en)	2015-04-15	Antibodies
GB201513447D0 (en)	2015-09-16	Antibody
GB201515570D0 (en)	2015-10-14	Anti-LAG-3 antibodies
GB201508257D0 (en)	2015-06-24	Antibody formulations
GB201507541D0 (en)	2015-06-17	Antibodies
GB201504858D0 (en)	2015-05-06	Antibodies
GB201502591D0 (en)	2015-04-01	Antibodies